Gamida Cell Ltd. (NASDAQ:GMDA) reported Q2 EPS of ($0.31), $0.02 worse than the analyst estimate of ($0.29).
Finished second quarter of 2022 with $55.1 million in cash; sufficient funding for the company’s operations into mid-2023, excluding the cost of commercializing omidubicel.